Status:
RECRUITING
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
Lead Sponsor:
Peking University Third Hospital
Conditions:
Ovarian Neoplasms
Eligibility:
FEMALE
18+ years
Brief Summary
The aim of this project is to establish a bidirectional multicenter cohort of hereditary ovarian cancer and to describe the clinicopathologic features of hereditary ovarian cancer patients in our coun...
Detailed Description
About 10%-20% of ovarian cancers have familial aggregation, suggesting that it may be hereditary ovarian cancer. Exploring a genetic ovarian cancer risk prediction model suitable for Chinese people wi...
Eligibility Criteria
Inclusion
- Epithelial ovarian cancer
- ≥18 years
- The pathological diagnosis was clear
- The genetic test showed germ line pathogenic/suspected pathogenic mutations (for mutation interpretation, refer to the American ACMG Classification Standards and Guidelines for Genetic Variation)
Exclusion
- Non-epithelial ovarian cancer was confirmed by pathology
- No genetic test has been performed
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06564428
Start Date
January 1 2024
End Date
December 31 2026
Last Update
June 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100000